ReviewJournal of lipid and atherosclerosis2021
Zebrafish as an Emerging Model for Dyslipidemia and Associated Diseases.
Review in Journal of lipid and atherosclerosis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 39 citations in OpenAlex.
- Protective Effects of Policosanol and Atorvastatin Co-Supplementation Against High-Cholesterol and High-Galactose Diet-Induced Metabolic and Organ Dysfunction in Zebrafish.International journal of molecular sciences · 2026Article
- A Framework for Selecting Zebrafish Models of Metabolic Diseases: Modeling Strategies, Phenotypic Validation, Mechanistic Investigation, and Efficacy Evaluation.Biomedicines · 2026Review
- Comparison of HDL-Associated Antioxidant Activities and Anti-Inflammatory Effect Between Ozonated Sunflower Oil (OSO) and Ozonated Olive Oil (OOO) Under Carboxymethyllysine-Induced Acute Phase in Zebrafish Adults and Embryos.Antioxidants (Basel, Switzerland) · 2026Article
- Selective targeting of kinesin on lipid droplets in the liver reduces plasma lipids.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Identification of Bioactive Medium Chain Fatty Acids (CAntioxidants (Basel, Switzerland) · 2026Article
- Combination of Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2026Article
- Cuban Sugarcane Wax Alcohol Supplementation Prevents Brain and Eye Damages of Zebrafish Exposed to High-Cholesterol and High-Galactose Diet for 30 Weeks: Protection of Myelin, Cornea, and Retina.Antioxidants (Basel, Switzerland) · 2025Article
- Directly Measuring Atherogenic Lipoprotein Kinetics in Zebrafish With the Photoconvertible LipoTimer Reporter.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- Adverse Effect of Sugarcane Extract Powder (SEP) in Hyper-Lipidemic Zebrafish During a 14-Week Diet: A Comparative Analysis of Biochemical and Toxicological Efficacy Between Four SEPs and Genuine Policosanol (RaydelInternational journal of molecular sciences · 2025Article
- Article
- Current status and challenges of multi-omics research using animal models of atherosclerosis.Journal of molecular and cellular cardiology plus · 2025Review
- Investigating Psychopharmaceutical Effects on Early Vertebrate Development Using a Zebrafish Model System.Journal of developmental biology · 2025Article
- Synergistic Effect of Banaba Leaf Extract and Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2025Article
- Drug screening for ischemic stroke using larvae and adult zebrafish model: a review.Laboratory animal research · 2025Review
- Non-rodent Models of Atherosclerosis: Repurposing of Existing Drugs and Search for Novel Treatment Strategies.Current cardiology reviews · 2025Review
- 2-Acetamidophenol (2-AAP) Suppresses the Progression of Atherosclerosis by Alleviating Hyperlipidemia and Attenuating the Ferroptosis Pathway.Marine drugs · 2024Article
- Zebrafish ApoB-Containing Lipoprotein Metabolism: A Closer Look.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Long-Term Supplementation of Royal Jelly (RaydelPharmaceuticals (Basel, Switzerland) · 2024Article
- Zebrafish as a Model for Lipidomics and Similar Investigations.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Consumption of Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dyslipidemia related diseases such as hyperlipidemia and atherosclerosis are the leading cause of death in humans. While cellular and molecular basis on the pathophysiology of dyslipidemia has been extensively investigated over decades, we still lack comprehensive understanding on the etiology of dyslipidemia due to the complexity and the innate multimodality of the diseases. While mouse has been the model organism of choice to investigate the pathophysiology of human dyslipidemia, zebrafish, a small freshwater fish which has traditionally used to study vertebrate development, has recently emerged as an alternative model organism. In this review, we will provide comprehensive perspective on zebrafish as a model organism for human dyslipidemia; we will discuss the attributes of zebrafish as a model, and compare the lipid metabolism in zebrafish and humans. In addition, we will summarize current landscape of zebrafish-based dyslipidemia research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.